{"id":2644,"date":"2015-06-04T20:43:00","date_gmt":"2015-06-04T20:43:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2644"},"modified":"2025-01-16T15:33:25","modified_gmt":"2025-01-16T15:33:25","slug":"the-disease-burden-of-hepatitis-c-in-belgium-an-update-of-a-realistic-disease-control-strategy","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/the-disease-burden-of-hepatitis-c-in-belgium-an-update-of-a-realistic-disease-control-strategy\/","title":{"rendered":"La charge de morbidit\u00e9 de l'h\u00e9patite C en Belgique: mise \u00e0 jour d'une strat\u00e9gie r\u00e9aliste de lutte contre la maladie"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Arri\u00e8re-plan<\/h3>\n\n\n\n

Ce manuscrit sert de mise \u00e0 jour aux prises de position publi\u00e9es en 2014 sur la base des donn\u00e9es \u00e9pid\u00e9miologiques disponibles sur le virus belge de l'h\u00e9patite C (VHC).<\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

S'appuyant sur la norme de soins actuelle (2015: 900 = patients F3 trait\u00e9s avec 70-85% SVR), quatre nouveaux sc\u00e9narios ont \u00e9t\u00e9 d\u00e9velopp\u00e9s pour atteindre les objectifs de quasi-\u00e9limination virale et de pr\u00e9vention de la morbidit\u00e9 et de la mortalit\u00e9 associ\u00e9es au VHC d'ici 2026 et 2031. l'efficacit\u00e9 du traitement a \u00e9t\u00e9 pr\u00e9sum\u00e9e en 2016 (90% SVR) et 2017 (95% SVR).<\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

Sc\u00e9nario 1: Traiter 6670 patients annuellement d'ici 2018 (= F0 \u00e0 partir de 2017) et diagnostiquer 3790 patients annuellement d'ici 2020, une r\u00e9duction 90% des cas vir\u00e9miques et des r\u00e9sultats avanc\u00e9s a \u00e9t\u00e9 observ\u00e9e d'ici 2026. Sc\u00e9nario 2: Traiter 4300 patients annuellement d'ici 2018 (= F0 \u00e0 partir de 2020) sans augmenter le nombre diagnostiqu\u00e9, une r\u00e9duction de 90% des cas vir\u00e9miques et de 85%-95% des r\u00e9sultats avanc\u00e9s a \u00e9t\u00e9 observ\u00e9e d'ici 2031. Sc\u00e9nario 3: Traiter 5 000 = F2 patients par an d'ici 2018 et diagnostiquer 3 620 patients par an d'ici 2020, a Une r\u00e9duction de 90% des r\u00e9sultats avanc\u00e9s et une r\u00e9duction de 50% des cas vir\u00e9miques ont \u00e9t\u00e9 observ\u00e9es d'ici 2026. Sc\u00e9nario 4: Traitement de 3100 patients = F2 par an d'ici 2018 sans augmenter le nombre diagnostiqu\u00e9, une r\u00e9duction de 90%-95% des r\u00e9sultats avanc\u00e9s et une r\u00e9duction de 55% des cas vir\u00e9miques ont \u00e9t\u00e9 observ\u00e9es par 2031.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Le sc\u00e9nario 2 fournirait l'\u00e9quilibre le plus favorable entre les r\u00e9sultats (r\u00e9duction de 90% de la pr\u00e9valence vir\u00e9mique et les r\u00e9sultats avanc\u00e9s) et les exigences r\u00e9alistes pour la mise en \u0153uvre (augmentation progressive du traitement, incorporation retard\u00e9e des patients sans fibrose \/ l\u00e9g\u00e8re fibrose).<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background This manuscript serves as an update to position papers published in 2014 based on the available Belgian hepatitis C virus (HCV) epidemiological data. Methods Building on the current standard of care (2015: 900 = F3 patients treated with 70-85% SVR), four new scenarios were developed to achieve the goals of near viral elimination […]<\/p>\n","protected":false},"author":24,"featured_media":3493,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[488,1134,2095,494,1136,895,1132,1135],"class_list":["post-2644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-blach-s","publication-author-laleman-w","publication-author-moreno-c","publication-author-razavi-h","publication-author-starkel-p","publication-author-van-damme-p","publication-author-van-vlierberghe-h","publication-author-vandijck-d"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2644"}],"version-history":[{"count":8,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2644\/revisions"}],"predecessor-version":[{"id":7607,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2644\/revisions\/7607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3493"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2644"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}